Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Traditionally, overall survival (os) has been considered the “gold standard” for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy in...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Hotte, S.J., Bjarnason, G.A., Heng, D.Y.C., Jewett, M.A.S., Kapoor, A., Kollmannsberger, C., Maroun, J., Mayhew, L.A., North, S., Reaume, M.N., Ruether, J.D., Soulieres, D., Venner, P.M., Winquist, E.W., Wood, L., Yong, J.H.E., Saad, F.
格式: Artigo
語言:Inglês
出版: Multimed Inc. 2011
主題:
Medical Oncology
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176905/
https://ncbi.nlm.nih.gov/pubmed/21969807
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍